Detection of the non-steroidal anti-inflammatory drug niflumic acid in humans: A combined 19F-MRS in vivo and in vitro study

NMR in Biomedicine

Volumn 16, Issue 3, 2003, Pages 144-151

  Bilecen, Deniz ^a   Schulte, Anja Carina ^b   Kaspar, Armin ^c   Küstermann, Eckerhardt ^c   Seelig, Joachim ^c   Elverfeldt, Dominik V ^b   Scheffler, Klaus ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

19F NMR; Human liver; Niflumic acid; Non steroidal anti inflammatory drugs

Indexed keywords

INORGANIC ACIDS; METABOLISM; SPECTROSCOPIC ANALYSIS;

ANTI-INFLAMMATORY DRUGS;

DRUG THERAPY;

DRUG METABOLITE; FLUORINE; HYDROXYL GROUP; LIVER ENZYME; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTICLE; BILIARY EXCRETION; CHEMICAL MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG LIVER LEVEL; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DENATURATION; SIGNAL DETECTION; TIME; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD CHEMICAL ANALYSIS; FLUORINE; HUMANS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC CLEARANCE RATE; NIFLUMIC ACID; ORGAN SPECIFICITY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; URINALYSIS;

EID: 0041629171     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.820     Document Type: Article

References (29)

1. Bolo NR, Hode Y, Nedelec J, Laine E, Wagner G, Macher J. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000; 23: 428-438.
2. 19F magnetic resonance spectroscopy. Am. J. Psychiat. 1998; 155: 380-384.
3. 19F magnetic resonance spectroscopy investigation in vivo of acute and steadystate brain fluvoxamine levels in obsessive compulsive disorders. Am. J. Psychiat. 1997; 154: 516-522.
4. 19F nuclear magnetic resonance of a monofluorinated neuroleptic in the rat. NMR Biomed. 1993; 6: 27-31.
5. 19F-magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluorperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biol. Psychiat. 1991; 30: 656-662.
6. 19F-magnetic resonance spectroscopy. Cancer Invest. 2000; 18: 20-7.
7. 19F NMR spectroscopic studies of the metabolism of 5-fluoruracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imag. 1987; 5: 165-169.
8. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug. Deliv. Rev. 2000; 15; 41: 55-74.
9. 19F-MRS. Magn. Reson. Imag. 1999; 17: 283-290.
10. 19F MR imaging. Imag. Reson. Imag. 1999; 17: 151-155.
11. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluoruracil with clinical response. Lancet 1994; 343: 1184-1187.
12. Litt L, Gonzales-Mende R, James TL, Sessler DI, Mills P, Chew WM, Moseley M, Pereira B, Severinghaus JW, Hamilton JK. An in vivo study of halothane uptake and elimination in the rat brain with fluorine magnetic resonance spectroscopy. Anaethesiology 1987; 67: 167-168.
13. 19F NMR study of isoflurane elimination as a function of age in rat brain. NMR Biomed. 1992; 5: 121-126.
14. 19F NMR spectroscopy. NMR Biomed. 1991; 4: 161-166.
15. Caldwell J. Intermediary xenobiotic metabolism in animals. Taylor and Francis: London 1990; 3-12.
16. 19F NMR. NMR Biomed. 1991; 4: 225-261.
17. Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. Pharmacokinetics of low-does oral modified release, soluble and intravenous aspirin in man and effects on platelet functions. Eur. J. Clin. Pharmac. 1988; 35: 287-294.
18. Flower RS, Moncada S, Vane JR. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics, Gillman AG, Goodman LS, Rall TW, Murad F (eds). Macmillan: New York, 1992; 674-715.
19. 14C: absorption, excretion and biotransformation by human and dog. J. Pharmac. Exp. Ther. 1973; 186: 323-330.
20. Johnson JL, Wimsatt J, Buckel SD, Dyer RD, Maddipati KR. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch. Biochem. Biophys. 1995; 26: 26-34.
21. Houin G, Tremblay D, Bree F, Dufour A, Ledudal P, Tillment JP. The pharmacokinetics and availability of niflumic acid in humans. Int. J. Clin. Pharmac. Ther. Toxicol. 1983; 21: 130-134.
22. Lopez CH, Bracht A, Yamamoto NS, Ishii-lwamoto EL, Samaio E, Kelmer-Bracht AM. The action of flufenamic acid and other nonsteroidal anti-inflammatories on sulfate transport in the isolated perfused rat liver. Gen. Pharmac. 1999; 32: 713-720.
23. Kelmer-Bracht AM, Ishii-Iwamaoto EL, Bracht A. Intracellular binding of the anti-inflammatory drug niflumic acid in the liver. Res. Commun. Mol. Pathol. Pharmac. 1995; 89: 411-419.
24. Evelhoch JL, Crowley MG, Ackerman JJH. Signal-to-noise optimization and observed volume localization with circular surface coils. J. Magn. Reson. 1984; 56: 110-124.
25. Tofts PS. The noninvasive measurement of absolute metabolite concentrations in vivo using surface coil NMR spectroscopy. J. Magn. Reson. 1988; 80: 84-95.
26. Kelmer-Bracht AM, Ishii-Iwamoto EL, Bracht A. Transport, distribution space and intracellular concentration of the anti-inflammatory drug niflumic acid in the perfused rat liver. Biochem. Pharmac. 1993; 45(9): 1863-1871.
27. 19F NMR of suspended leukemic cells. NMR Biomed. 1993; 6: 125-129.
28. 19F NMR chemical shift difference of fluorinated solutes in liposomes, erythrocytes and erythrocyte ghosts. NMR Biomed. 1993; 6: 136-143.
29. Mooney EF. Annual Reports on NMR Spectroscopy. Academic Press: London, 1972.